Therapixel, a Nice, Paris-France- and Chicago, IL-based company focused on the design and commercialization of AI-powered medical imaging software, raised €15M in Series B funding.
The round was led by Crédit Mutuel Innovation and CapHorn, with participation from Verve, Sham Innovation Santé, Omnes, IT-Translation, M-Capital and Région Sud Investissement.
The company intends to use the funds to accelerate its commercial presence in the United States, and launch more features for MammoScreen.
Therapixel’s CEO Matthieu Léclerc-Chalvet and its Chief Scientific and Technology Officer Pierre Fillard are leading the effort to design and market AI-powered medical imaging software. Their goal is to provide relevant information to healthcare professionals at the right time. MammoScreen is a software program that aids in the interpretation of screening mammograms.
MammoScreen already has two FDA regulatory clearances for mammography in the United States. This is for both 2D (tomosynthesis), and 3D (tomosynthesis). It uses a score that indicates at a glance how suspicious a mammogram looks. This makes it easy to identify lesions which are likely and saves time by allowing for faster diagnosis of benign cases.